Navigation Links
YM BioSciences presents CYT387 and CYT997 data at international cancer conference
Date:2/11/2010

"xn-chron">4:00am EST).

Dr. Andrew Powell, Preclinical Project Manager at YM Australia, will present the poster on the vascular disrupting agent, CYT997, which is currently in a Phase II trial for glioblastoma multiforme, a brain cancer with very poor prognosis, despite multimodal treatment. The poster outlines data from preclinical studies demonstrating the profound vascular disrupting effects achieved with CYT997 through repeated oral daily dosing. In addition, data will be presented showing that a combination of the conventional chemotherapeutic agent cisplatin with daily dosing of CYT997 leads to an improved response in a model of colon cancer.

Additional information on the Lorne Cancer Conference is available at www.lornecancer.org. Abstracts for both posters will be posted at the time of presentation at www.ymbiosciences.com.

About YM BioSciences

YM BioSciences Inc. is a life sciences product development. Together with the products from YM Australia (formerly Cytopia Limited), the Company is currently developing four late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM); CYT 387, a JAK 1/2 small molecule inhibitor, CYT 997, a potent, vascular disrupting agent and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward in
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BioSciences granted two US patents for AeroLEF(R)
2. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
3. YM BioSciences reports second quarter 2010 operational and financial results
4. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
5. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
6. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
7. Cellectricon Files Patent Infringement Suit Against Fluxion Biosciences
8. YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
9. YM BioSciences announces result of Cytopia shareholder vote
10. Profectus Biosciences to Present at Key Investor Conference in January 2010
11. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 DTS Language Services, ... Online Web Portal for Life Science organizations who need document ... the subject matter of their documents in advance with a ... reduce time-to-delivery of translations, often a critical factor in clinical ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. – ... Warrington, Pa. , Details: The Hepatitis B Foundation, ... cure for hepatitis B and improving the quality of life ... on Friday, April 11 at Warrington Country Club in Warrington, ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... WESTBOROUGH, Mass. , Jan. 14, 2014  RXi ... on discovering, developing and commercializing innovative therapies addressing ... announced that it received the Notice of Allowance ... on its unique self-delivering RNAi compounds (sd-rxRNA®), for ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... be the nation,s next "Strontium Valley"? The University of Pittsburgh ... the National Science Foundation and the Nanoelectronics Research Initiative (NRI) ... kind of computer out of the lab and into the ... Levy, a professor of physics and astronomy in Pitt,s School ...
... 19, 2011 Reportlinker.com announces that a ... its catalogue: Established and ... http://www.reportlinker.com/p0618133/Established-and-Emerging-Biotech-Clusters.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biotechnology There has ... clusters of biotechnology companies and related organizations. ...
... HAYWARD, Calif., Sept. 19, 2011 OptiScan Biomedical ... systems for use in intensive care units (ICU), ... Glucose Monitoring System has received CE Mark certification ... Mark certifies that the OptiScanner has met all ...
Cached Biology Technology:Post-silicon computing 2Post-silicon computing 3Post-silicon computing 4Established and Emerging Biotech Clusters 2Established and Emerging Biotech Clusters 3Established and Emerging Biotech Clusters 4Established and Emerging Biotech Clusters 5Established and Emerging Biotech Clusters 6Established and Emerging Biotech Clusters 7Established and Emerging Biotech Clusters 8OptiScan Biomedical Receives CE Mark for OptiScanner Automatic Bedside Glucose Monitoring System 2OptiScan Biomedical Receives CE Mark for OptiScanner Automatic Bedside Glucose Monitoring System 3OptiScan Biomedical Receives CE Mark for OptiScanner Automatic Bedside Glucose Monitoring System 4
(Date:4/17/2014)... way the immune system may fight cancers and viral ... cells to treat illness. , The research, in mice, ... "neighborhood police" specialized squads of defenders that patrol ... entire city, the body. , Scientists at Washington University ... the liver, skin and uterus each has dedicated immune ...
(Date:4/17/2014)... domestication derive from Charles Darwin, whose ideas in ... during the 19th century, a period when landowners ... is from Darwin that we inherit the ideas ... wild species and total human control over breeding ... this industrial setting has been applied too broadly ...
(Date:4/16/2014)... have identified a new syndrome called "osteosarcopenic obesity" that ... with obesity. , "It used to be the thinking ... would be because the bones were supporting more weight," ... at Florida State. "But, that,s only true to a ...
Breaking Biology News(10 mins):Some immune cells defend only 1 organ 2The story of animal domestication retold 2The story of animal domestication retold 3The story of animal domestication retold 4Researchers: Obesity can amplify bone and muscle loss 2
... GAINESVILLE, Fla. Hit-and-run attacks by sharks can be ... by the unique chomp they put on their victims, ... expert. In a method analogous to analyzing human ... bites to the jaws and teeth of the powerful ...
... Charles Darwin it was an ,abominable mystery, and it is a ... did flowering plants evolve and how did they come to dominate ... reveals the evolutionary trigger which led to early flowering plants ... subsequent boom and abundance. The study, by Dr Tim Brodribb ...
... The first comprehensive review of the state of Antarctica,s ... is published this week (Tuesday 1 December) by the ... - Antarctic Climate Change and the Environment presents ... for future scientific research, and addresses the urgent questions ...
Cached Biology News:New forensic technique gives clues about sharks from bite damage 2New forensic technique gives clues about sharks from bite damage 3How did flowering plants evolve to dominate Earth? 2First comprehensive review of the state of Antarctica's climate 2
... is formulated for covering tissue sections and cell preparations immunohistochemically ... products. , ... Application: Vision ... AEC that require an aqueous mounting medium, or those that ...
... Target Retrieval Solution, High pH ... heat-induced target retrievel prior to immunohistochemical staining ... paraffin-embedded tissue sections mounted on glass slides. ... pH, 9.9, is especially effective. It should ...
Collected from calves that are 10 days old or less. Sterile, cell culture tested, US Origin...
... High pH, Concentrated x 10 This ... target retrievel prior to immunohistochemical staining procedures. ... tissue sections mounted on glass slides. For ... 9.9, is especially effective. It should be ...
Biology Products: